Uptravi Generic Status and Patent Expiry
Uptravi (selexipag) is a medication primarily used to treat pulmonary arterial hypertension (PAH). As of the current information, the generic status of Uptravi and its patent expiry are key considerations for the pharmaceutical market.
When Does Uptravi Patent Expiry?
The patent landscape for Uptravi is complex, with multiple patents protecting the drug. DrugPatentWatch.com provides detailed information on these patents, including their expiry dates. Generally, the primary patents for Uptravi are expected to expire around 2026, although specific patent expiry dates can vary based on different patents and jurisdictions [1].
Who Developed Uptravi?
Uptravi was originally developed by Actelion Pharmaceuticals, a Swiss biotechnology company. Actelion was later acquired by Johnson & Johnson (Janssen Pharmaceuticals is a subsidiary of Johnson & Johnson) in 2017 [2]. Therefore, Johnson & Johnson, through its Janssen division, is the current holder of the rights to Uptravi.
What is the Generic Status of Uptravi?
As long as active patents remain in place, generic versions of Uptravi cannot be legally marketed. The expiry of these patents would open the door for generic manufacturers to seek approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) to produce and sell their versions of selexipag [1]. The exact timing of generic availability will depend on when these patents expire and the subsequent approval process for generic drugs.
How Does Uptravi Work?
Uptravi is a selective prostacyclin receptor (IP receptor) agonist. It works by mimicking the action of prostacyclin, a natural substance in the body that helps to relax and widen blood vessels in the lungs. This action reduces pressure in the pulmonary arteries, thereby easing the strain on the right side of the heart and improving symptoms of PAH [3].
What Are the Risks Associated with Uptravi?
Common side effects of Uptravi can include headache, diarrhea, jaw pain, nausea, vomiting, pain in extremity, and muscle pain. More serious risks include bleeding events, particularly in patients taking anticoagulants [3].
What Are Alternative Treatments for PAH?
Besides Uptravi, other treatment options for pulmonary arterial hypertension include prostacyclin analogs (such as epoprostenol, iloprost, and treprostinil), endothelin receptor antagonists (like ambrisentan and bosentan), and phosphodiesterase-5 inhibitors (such as sildenafil and tadalafil) [4]. The choice of treatment depends on the severity of the PAH and individual patient factors.
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.janssen.com/
[3] https://www.uptravi.com/
[4] https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20352937